Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Framework vs PauseRX

Framework
Graded #485

Lower grade

vs+16.9
PauseRX
Graded #147

Higher grade

The verdict

PauseRX takes it — 68.5/100 to 51.6/100.

PauseRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePauseRX +21
45
66
Dose & formulationPauseRX +45
40
85
Clinical oversightPauseRX +11
72
83
Labs & monitoringEven
52
52
FulfillmentPauseRX +4
57
61
Contract termsEven
41
41
Framework · left barPauseRX · right bar

The numbers

MetricFrameworkPauseRX
WeighScore51.6/10068.5/100
GradeCC
Scorecard rank#485#147
SemaglutideNot disclosed$199/mo
TirzepatideNot disclosed$249/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Framework

Graded #485 · C

Strengths

  • The compounding pharmacy partner is named, which most of this field does not do
  • Treatment selection is doctor-guided rather than a fixed product menu
  • US-licensed clinicians and a 503A pharmacy pathway

Where it loses points

  • No monthly medication price is published: the tirzepatide and semaglutide pages carry no price at all, and the homepage advertises a per-week figure for 'GLP-1s' generally rather than a rate for either drug
  • The only drug-specific prices anywhere on the site sit on a legacy page — semaglutide at $349 per three months and tirzepatide at $549 per three months
  • A '$75/month with 3-month package' figure is footnoted as a promotion for new GLP-1 users only
  • Different landing pages advertise different per-week rates, $25 on one and $19 on another
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
PauseRX

Graded #147 · C

Strengths

  • Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
  • Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
  • Publishes the FDA compounded-medication disclaimer
  • Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
  • Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation

Where it loses points

  • States served not listed — site claims nationwide, but you must contact support to confirm availability
  • Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
  • No named medical director (Beluga Health is the network, not a named MD)
  • LegitScript certification number not shown — badge only, so no direct lookup
  • Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard